search
Back to results

Prevention of Post-Operative Cardiac Arrhythmias (POCA)

Primary Purpose

Cardiac; Dysrhythmia, Postoperative, Congenital Heart Surgery

Status
Not yet recruiting
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Dexmedetomidine
Magnesium Sulfate
Amiodarone
Procainamide
Sponsored by
Jeffrey Moak
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cardiac; Dysrhythmia, Postoperative focused on measuring Magnesium Sulfate, Dexedetomidine, anti-arrhythmic medications

Eligibility Criteria

undefined - 35 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 1) Any infant, child, adolescent, or young adult with congenital or acquired heart disease undergoing open heart surgical repair using cardiopulmonary bypass is eligible to be enrolled in this trial.
  • 2) No age, gender or ethnic group restrictions.

Exclusion Criteria:

  • 1) Non-cardiopulmonary bypass repair of a congenital or acquired cardiac defect.
  • 2) Significant pre-operative arrhythmia history
  • 3) Past history of adverse effect to any of the study medication agents

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Active Comparator

    Active Comparator

    Active Comparator

    Active Comparator

    Arm Label

    Stage 1, Group 1 - Dexmedetomidine

    Stage 1, Group 2- Magnesium

    Stage 2, AMIODARONE

    Stage 2, PROCAINAMIDE

    Arm Description

    Dexmedetomidine: 1 mcg/kg administered at end of cardiopulmonary bypass, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period

    Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day.

    AMIODARONE I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours

    PROCAINAMIDE IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min

    Outcomes

    Primary Outcome Measures

    Incidence of Post-Operative Cardiac Arrhythmias
    The investigator will determine the incidence of cardiac arrhythmia in the two study groups (dexmedetomidine and magnesium sulfate). Statistical analysis will be performed to determine whether a statistical difference is detected between the two study groups. The occurrence of cardiac arrhythmias will be determined from continuous cardiac telemetry.

    Secondary Outcome Measures

    Percent of Treatment Success Following IV Amiodarone or Procainamide Administration for Post-Operative Cardiac Arrhythmias.
    The investigator will determine treatment success (as measured by the composite of complete or partial arrhythmia control) following the administration of either IV amiodarone or procainamide administration. Percent of treatment success will be determined by the composite success group divided by all given administered each anti-arrhythmic agent. Statistical analysis will be performed to determine whether a statistical difference is detected between the two study groups. Arrhythmia control will be determined from continuous cardiac telemetry.
    Incidence of Adverse Effects following IV Amiodarone or Procainamide Administration
    The investigator will determine the incidence of adverse effects (hypotension, bradycardia, or low cardiac output) following the administration of either IV amiodarone or procainamide. Statistical analysis will be performed to determine whether a statistical difference is detected between the two study groups.

    Full Information

    First Posted
    January 6, 2020
    Last Updated
    March 12, 2022
    Sponsor
    Jeffrey Moak
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04234906
    Brief Title
    Prevention of Post-Operative Cardiac Arrhythmias
    Acronym
    POCA
    Official Title
    Multicenter Study for the Prevention of Post-Operative Cardiac Arrhythmias
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    December 2021
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    January 2023 (Anticipated)
    Primary Completion Date
    April 2023 (Anticipated)
    Study Completion Date
    August 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Jeffrey Moak

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    Yes
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Aim 1: Primary Prevention of Post-operative Cardiac Arrhythmias To evaluate the efficacy of dexmedetomidine vs. the combination of Magnesium Sulfate and dexmedetomidine for the prevention of post-operative cardiac arrhythmias in children and young adults undergoing open heart surgical repair for congenital or acquired heart disease using cardiopulmonary bypass. Dexmedetomidine is currently being administered to almost all patients after coming off cardiopulmonary bypass and in the CICU. For this aim, the investigator will be comparing dexmedetomidine administered alone or in combination with Magnesium Sulfate. To evaluate medication safety based on the frequency of Serious Adverse Events (SAEs) and Adverse Events (AEs) Aim 2: Secondary treatment of those Patients that develop a clinically significant arrhythmia despite having received either Dexmedetomidine alone or Magnesium Sulfate with Dexmedetomidine at the time of cardiac surgery To evaluate the efficacy of intravenous (IV) Amiodarone vs. IV Procainamide for the control of postoperative cardiac arrhythmias developing after the failure of Stage 1, Preventative Trial. IV amiodarone and IV procainamide are standardly used treatment agents for the treatment of postoperative cardiac arrhythmias in this setting. The investigator will be assessing the comparative effectiveness of these agents in controlling post-operative cardiac arrhythmias. To evaluate antiarrhythmic medication safety based on the frequency of SAEs and AEs
    Detailed Description
    Objective: Postoperative cardiac arrhythmias (POCA) are common in children undergoing congenital heart surgery using the heart-lung machine (cardiopulmonary bypass) and have been reported in 5-38% of patients. The occurrence of arrhythmias frequently delays the patient's postoperative recovery, prolongs Cardiac Intensive Care Unit (CICU) and hospital stay, increases costs for hospital care and increases postoperative morbidity and mortality. Magnesium Sulfate has been one agent used to reduce the occurrence of postoperative arrhythmias. The investigators recently published a propensity-score matched study of the intra-operative administration of Magnesium Sulfate revealing that as many as one-third of pediatric patients at Children's National Hospital undergoing open-heart surgery using cardiopulmonary bypass have postoperative arrhythmias. The use of intraoperative Magnesium Sulfate was associated with a reduction in the occurrence of postoperative arrhythmias. However, despite the intraoperative use of Magnesium Sulfate there continued to be a fairly high residual occurrence rate of post-operative arrhythmias (total arrhythmia frequency -18%). Dexmedetomidine has also been showed to reduce the occurrence of POCA and has become the preferred agent used for post-operative sedation and pain control. In several studies reported in the medical literature, dexmedetomidine has been found to decrease the occurrence of POCA, like Magnesium Sulfate. In this IRB study, the investigator is proposing a clinical study to test if the investigator can further decrease the occurrence of postoperative arrhythmias. The investigator will be studying if Magnesium Sulfate administrated in conjunction with an intravenous anesthetic medication, known as dexmedetomidine, can further decrease the primary occurrence of post-operative arrhythmias. The investigator hypothesizes that the effect achieved with the simultaneous administration of Magnesium Sulfate and dexmedetomidine will be much greater than either medication used alone. For those patients who fail preventative medical strategies and develop clinical significant post-operative arrhythmias in need of treatment, rescue arrhythmia treatment options include the use of potent anti-arrhythmic medications that can have very dramatic effects on the patient's heart rate and blood pressure (amiodarone or procainamide). Scant published data exists providing us with guidance on the comparative efficacy and safety of these agents in the postoperative cardiac surgical patient. The investigator will compare the efficacy and adverse effects of the two agents in treating clinically significant arrhythmias that occur despite trying to prevent their onset.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cardiac; Dysrhythmia, Postoperative, Congenital Heart Surgery
    Keywords
    Magnesium Sulfate, Dexedetomidine, anti-arrhythmic medications

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Sequential Assignment
    Model Description
    Two staged, prospective randomized clinical trial: Stage 1 targets prevention of post-operative arrhythmias. Stage 2 allows for re-randomization to secondary treatment for those subjects failing Stage 1, i.e. those patients that develop and require treatment of clinically significant post-operative cardiac arrhythmias with antiarrhythmic medication.
    Masking
    None (Open Label)
    Masking Description
    Patients will be randomized within each participating center, not by center, into study groups: Stage 1: Group 1 - Dexmedetomidine vs. Group 2- Magnesium Sulfate + Dexmedetomidine Stage 2: If clinically significant arrhythmias in need of treatment develop, patients will be randomized to Group 1 - amiodarone vs. procainamide. Randomization will occur through a module in Redcap.
    Allocation
    Randomized
    Enrollment
    870 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Stage 1, Group 1 - Dexmedetomidine
    Arm Type
    Active Comparator
    Arm Description
    Dexmedetomidine: 1 mcg/kg administered at end of cardiopulmonary bypass, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period
    Arm Title
    Stage 1, Group 2- Magnesium
    Arm Type
    Active Comparator
    Arm Description
    Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day.
    Arm Title
    Stage 2, AMIODARONE
    Arm Type
    Active Comparator
    Arm Description
    AMIODARONE I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours
    Arm Title
    Stage 2, PROCAINAMIDE
    Arm Type
    Active Comparator
    Arm Description
    PROCAINAMIDE IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min
    Intervention Type
    Drug
    Intervention Name(s)
    Dexmedetomidine
    Other Intervention Name(s)
    Precedex
    Intervention Description
    Dexmedetomidine: 1 mcg/kg administered over 20 min peri-intubation period, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period
    Intervention Type
    Drug
    Intervention Name(s)
    Magnesium Sulfate
    Intervention Description
    Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day
    Intervention Type
    Drug
    Intervention Name(s)
    Amiodarone
    Intervention Description
    I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours
    Intervention Type
    Drug
    Intervention Name(s)
    Procainamide
    Other Intervention Name(s)
    Pronestyl
    Intervention Description
    IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min
    Primary Outcome Measure Information:
    Title
    Incidence of Post-Operative Cardiac Arrhythmias
    Description
    The investigator will determine the incidence of cardiac arrhythmia in the two study groups (dexmedetomidine and magnesium sulfate). Statistical analysis will be performed to determine whether a statistical difference is detected between the two study groups. The occurrence of cardiac arrhythmias will be determined from continuous cardiac telemetry.
    Time Frame
    3 years
    Secondary Outcome Measure Information:
    Title
    Percent of Treatment Success Following IV Amiodarone or Procainamide Administration for Post-Operative Cardiac Arrhythmias.
    Description
    The investigator will determine treatment success (as measured by the composite of complete or partial arrhythmia control) following the administration of either IV amiodarone or procainamide administration. Percent of treatment success will be determined by the composite success group divided by all given administered each anti-arrhythmic agent. Statistical analysis will be performed to determine whether a statistical difference is detected between the two study groups. Arrhythmia control will be determined from continuous cardiac telemetry.
    Time Frame
    3 years
    Title
    Incidence of Adverse Effects following IV Amiodarone or Procainamide Administration
    Description
    The investigator will determine the incidence of adverse effects (hypotension, bradycardia, or low cardiac output) following the administration of either IV amiodarone or procainamide. Statistical analysis will be performed to determine whether a statistical difference is detected between the two study groups.
    Time Frame
    3 years

    10. Eligibility

    Sex
    All
    Maximum Age & Unit of Time
    35 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: 1) Any infant, child, adolescent, or young adult with congenital or acquired heart disease undergoing open heart surgical repair using cardiopulmonary bypass is eligible to be enrolled in this trial. 2) No age, gender or ethnic group restrictions. Exclusion Criteria: 1) Non-cardiopulmonary bypass repair of a congenital or acquired cardiac defect. 2) Significant pre-operative arrhythmia history 3) Past history of adverse effect to any of the study medication agents
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jeffrey Moak
    Phone
    2024765707
    Email
    JMOAK@childrensnational.org
    First Name & Middle Initial & Last Name or Official Title & Degree
    Robert Lowndes
    Phone
    202-476-4970
    Email
    rlowndes@childrensnational.org
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jeffrey Moak
    Organizational Affiliation
    Children's National Research Institute
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    17382623
    Citation
    Rekawek J, Kansy A, Miszczak-Knecht M, Manowska M, Bieganowska K, Brzezinska-Paszke M, Szymaniak E, Turska-Kmiec A, Maruszewski P, Burczynski P, Kawalec W. Risk factors for cardiac arrhythmias in children with congenital heart disease after surgical intervention in the early postoperative period. J Thorac Cardiovasc Surg. 2007 Apr;133(4):900-4. doi: 10.1016/j.jtcvs.2006.12.011.
    Results Reference
    background
    PubMed Identifier
    12440616
    Citation
    Hoffman TM, Bush DM, Wernovsky G, Cohen MI, Wieand TS, Gaynor JW, Spray TL, Rhodes LA. Postoperative junctional ectopic tachycardia in children: incidence, risk factors, and treatment. Ann Thorac Surg. 2002 Nov;74(5):1607-11. doi: 10.1016/s0003-4975(02)04014-6.
    Results Reference
    background
    PubMed Identifier
    11986588
    Citation
    Dodge-Khatami A, Miller OI, Anderson RH, Goldman AP, Gil-Jaurena JM, Elliott MJ, Tsang VT, De Leval MR. Surgical substrates of postoperative junctional ectopic tachycardia in congenital heart defects. J Thorac Cardiovasc Surg. 2002 Apr;123(4):624-30. doi: 10.1067/mtc.2002.121046.
    Results Reference
    background
    PubMed Identifier
    7639165
    Citation
    Cecchin F, Johnsrude CL, Perry JC, Friedman RA. Effect of age and surgical technique on symptomatic arrhythmias after the Fontan procedure. Am J Cardiol. 1995 Aug 15;76(5):386-91. doi: 10.1016/s0002-9149(99)80106-4.
    Results Reference
    background
    PubMed Identifier
    11828284
    Citation
    Pfammatter JP, Wagner B, Berdat P, Bachmann DC, Pavlovic M, Pfenninger J, Carrel T. Procedural factors associated with early postoperative arrhythmias after repair of congenital heart defects. J Thorac Cardiovasc Surg. 2002 Feb;123(2):258-62. doi: 10.1067/mtc.2002.119701.
    Results Reference
    background
    PubMed Identifier
    23662635
    Citation
    Moak JP, Arias P, Kaltman JR, Cheng Y, McCarter R, Hanumanthaiah S, Martin GR, Jonas RA. Postoperative junctional ectopic tachycardia: risk factors for occurrence in the modern surgical era. Pacing Clin Electrophysiol. 2013 Sep;36(9):1156-68. doi: 10.1111/pace.12163. Epub 2013 May 10.
    Results Reference
    background
    PubMed Identifier
    29778339
    Citation
    He D, Aggarwal N, Zurakowski D, Jonas RA, Berul CI, Hanumanthaiah S, Moak JP. Lower risk of postoperative arrhythmias in congenital heart surgery following intraoperative administration of magnesium. J Thorac Cardiovasc Surg. 2018 Aug;156(2):763-770.e1. doi: 10.1016/j.jtcvs.2018.04.044. Epub 2018 Apr 18.
    Results Reference
    background
    PubMed Identifier
    25762470
    Citation
    He D, Sznycer-Taub N, Cheng Y, McCarter R, Jonas RA, Hanumanthaiah S, Moak JP. Magnesium Lowers the Incidence of Postoperative Junctional Ectopic Tachycardia in Congenital Heart Surgical Patients: Is There a Relationship to Surgical Procedure Complexity? Pediatr Cardiol. 2015 Aug;36(6):1179-85. doi: 10.1007/s00246-015-1141-5. Epub 2015 Mar 12.
    Results Reference
    background
    Citation
    Lapsa J, Clark B, Chen YI, Moak JP. Incidence and risk factors for development of post-operative bradyarrhythmias following congenital and acquired cardiac disease repair in pediatric patients. Poster at APS, Baltimore, MD, 2019.
    Results Reference
    background
    PubMed Identifier
    28249845
    Citation
    El Amrousy DM, Elshmaa NS, El-Kashlan M, Hassan S, Elsanosy M, Hablas N, Elrifaey S, El-Feky W. Efficacy of Prophylactic Dexmedetomidine in Preventing Postoperative Junctional Ectopic Tachycardia After Pediatric Cardiac Surgery. J Am Heart Assoc. 2017 Mar 1;6(3):e004780. doi: 10.1161/JAHA.116.004780.
    Results Reference
    background
    PubMed Identifier
    21871284
    Citation
    Chrysostomou C, Sanchez-de-Toledo J, Wearden P, Jooste EH, Lichtenstein SE, Callahan PM, Suresh T, O'Malley E, Shiderly D, Haney J, Yoshida M, Orr R, Munoz R, Morell VO. Perioperative use of dexmedetomidine is associated with decreased incidence of ventricular and supraventricular tachyarrhythmias after congenital cardiac operations. Ann Thorac Surg. 2011 Sep;92(3):964-72; discussion 972. doi: 10.1016/j.athoracsur.2011.04.099.
    Results Reference
    background
    PubMed Identifier
    20194798
    Citation
    Chang PM, Silka MJ, Moromisato DY, Bar-Cohen Y. Amiodarone versus procainamide for the acute treatment of recurrent supraventricular tachycardia in pediatric patients. Circ Arrhythm Electrophysiol. 2010 Apr;3(2):134-40. doi: 10.1161/CIRCEP.109.901629. Epub 2010 Mar 1.
    Results Reference
    background
    PubMed Identifier
    12760983
    Citation
    Jian W, Su L, Yiwu L. The effects of magnesium prime solution on magnesium levels and potassium loss in open heart surgery. Anesth Analg. 2003 Jun;96(6):1617-1620. doi: 10.1213/01.ANE.0000065444.21593.23.
    Results Reference
    background
    PubMed Identifier
    19819469
    Citation
    Manrique AM, Arroyo M, Lin Y, El Khoudary SR, Colvin E, Lichtenstein S, Chrysostomou C, Orr R, Jooste E, Davis P, Wearden P, Morell V, Munoz R. Magnesium supplementation during cardiopulmonary bypass to prevent junctional ectopic tachycardia after pediatric cardiac surgery: a randomized controlled study. J Thorac Cardiovasc Surg. 2010 Jan;139(1):162-169.e2. doi: 10.1016/j.jtcvs.2009.07.064. Epub 2009 Oct 12.
    Results Reference
    background
    PubMed Identifier
    12774159
    Citation
    Dittrich S, Germanakis J, Dahnert I, Stiller B, Dittrich H, Vogel M, Lange PE. Randomised trial on the influence of continuous magnesium infusion on arrhythmias following cardiopulmonary bypass surgery for congenital heart disease. Intensive Care Med. 2003 Jul;29(7):1141-4. doi: 10.1007/s00134-003-1802-3. Epub 2003 May 28.
    Results Reference
    background
    PubMed Identifier
    23443885
    Citation
    Lee HY, Ghimire S, Kim EY. Magnesium supplementation reduces postoperative arrhythmias after cardiopulmonary bypass in pediatrics: a metaanalysis of randomized controlled trials. Pediatr Cardiol. 2013 Aug;34(6):1396-403. doi: 10.1007/s00246-013-0658-8. Epub 2013 Feb 27.
    Results Reference
    background
    PubMed Identifier
    10689268
    Citation
    Dorman BH, Sade RM, Burnette JS, Wiles HB, Pinosky ML, Reeves ST, Bond BR, Spinale FG. Magnesium supplementation in the prevention of arrhythmias in pediatric patients undergoing surgery for congenital heart defects. Am Heart J. 2000 Mar;139(3):522-8. doi: 10.1016/s0002-8703(00)90097-8.
    Results Reference
    background
    PubMed Identifier
    20688775
    Citation
    Verma YS, Chauhan S, Gharde P, Lakshmy R, Kiran U. Role of magnesium in the prevention of postoperative arrhythmias in neonates and infants undergoing arterial switch operation. Interact Cardiovasc Thorac Surg. 2010 Nov;11(5):573-6. doi: 10.1510/icvts.2010.239830. Epub 2010 Aug 5.
    Results Reference
    background
    PubMed Identifier
    28688240
    Citation
    Fairley JL, Zhang L, Glassford NJ, Bellomo R. Magnesium status and magnesium therapy in cardiac surgery: A systematic review and meta-analysis focusing on arrhythmia prevention. J Crit Care. 2017 Dec;42:69-77. doi: 10.1016/j.jcrc.2017.05.038. Epub 2017 Jun 21.
    Results Reference
    background
    PubMed Identifier
    30260073
    Citation
    Li X, Zhang C, Dai D, Liu H, Ge S. Efficacy of dexmedetomidine in prevention of junctional ectopic tachycardia and acute kidney injury after pediatric cardiac surgery: A meta-analysis. Congenit Heart Dis. 2018 Sep;13(5):799-807. doi: 10.1111/chd.12674. Epub 2018 Sep 27.
    Results Reference
    background
    PubMed Identifier
    28774644
    Citation
    Gautam NK, Turiy Y, Srinivasan C. Preincision Initiation of Dexmedetomidine Maximally Reduces the Risk of Junctional Ectopic Tachycardia in Children Undergoing Ventricular Septal Defect Repairs. J Cardiothorac Vasc Anesth. 2017 Dec;31(6):1960-1965. doi: 10.1053/j.jvca.2017.04.010. Epub 2017 Apr 10.
    Results Reference
    background
    PubMed Identifier
    18089616
    Citation
    Mahmoud AB, Tantawy AE, Kouatli AA, Baslaim GM. Propranolol: a new indication for an old drug in preventing postoperative junctional ectopic tachycardia after surgical repair of tetralogy of Fallot. Interact Cardiovasc Thorac Surg. 2008 Apr;7(2):184-7. doi: 10.1510/icvts.2007.160945. Epub 2007 Dec 18.
    Results Reference
    background
    PubMed Identifier
    25878324
    Citation
    Shuplock JM, Smith AH, Owen J, Van Driest SL, Marshall M, Saville B, Xu M, Radbill AE, Fish FA, Kannankeril PJ. Association between perioperative dexmedetomidine and arrhythmias after surgery for congenital heart disease. Circ Arrhythm Electrophysiol. 2015 Jun;8(3):643-50. doi: 10.1161/CIRCEP.114.002301. Epub 2015 Apr 15.
    Results Reference
    background
    PubMed Identifier
    26818850
    Citation
    Amrousy DE, Elshehaby W, Feky WE, Elshmaa NS. Safety and Efficacy of Prophylactic Amiodarone in Preventing Early Junctional Ectopic Tachycardia (JET) in Children After Cardiac Surgery and Determination of Its Risk Factor. Pediatr Cardiol. 2016 Apr;37(4):734-9. doi: 10.1007/s00246-016-1343-5. Epub 2016 Jan 27.
    Results Reference
    background
    PubMed Identifier
    3358991
    Citation
    Lakatos E. Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics. 1988 Mar;44(1):229-41. Erratum In: Biometrics 1988 Sep;44(3):923.
    Results Reference
    background
    PubMed Identifier
    12111882
    Citation
    Lakatos E. Designing complex group sequential survival trials. Stat Med. 2002 Jul 30;21(14):1969-89. doi: 10.1002/sim.1193.
    Results Reference
    background

    Learn more about this trial

    Prevention of Post-Operative Cardiac Arrhythmias

    We'll reach out to this number within 24 hrs